Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/03/031844
CTRI/2021/03/031844
Not yet recruiting
未知

Patient specific three-dimensional printed models of aberrant anatomy for surgical planning of anorectal malformation

AIIMS Delhi0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
AIIMS Delhi
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
AIIMS Delhi

Eligibility Criteria

Inclusion Criteria

  • •Male patient with anorectal anomaly with colostomy done in neonatal period and waiting for a definitive repair in whom the pressure augmented colostogram does not reveal an obvious urethral communication with the terminal portion of bowel.

Exclusion Criteria

  • •1\. Patients in whom a prior lower abdominal/pelvic surgery/urological has been done before.
  • •2\. Patients in whom a prior surgery in the perineum or exploration has been done before.
  • •3\. Patients having a concomitant cardiac anomaly severe enough to preclude administering
  • •sedation or anesthesia as decided by a consultant anesthetist.
  • •4\. Patients in whom urethral catheterization fails by a trained surgical resident with a minimum
  • •of 3 yearsâ?? experience after medical graduation (senior resident).
  • •5\. ARM associated with caudal regression syndrome (a disorder that impairs the development
  • •of the lower (caudal) half of the body. Affected areas can include the lower back, sacrum, pelvis, limbs, the genitourinary tract, and the gastrointestinal tract.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 3
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Japanese Adults With Hypoparathyroidism
JPRN-jRCT2051210058Sibley Christopher12
Active, not recruiting
Not Applicable
Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast cancer defined as triple-negative tumor (HER2 negative - ER negative - PR negative) or HER2 negative and PR negative tumor; in node positive or node negative patients. - TavIx
EUCTR2006-006494-24-BEFédération Nationale des Centres de Lutte Contre le Cancer2,500
Active, not recruiting
Phase 3
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
2024-510704-37-00Unicancer1,000
Active, not recruiting
Phase 1
Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast cancer defined as triple-negative tumor (HER2 negative - ER negative - PR negative) or HER2 negative and PR negative tumor; in node positive or node negative patients. - TavIxnon-metastatic operable breast cancerMedDRA version: 9.1 Level: LLT Classification code 10006192 Term: Breast cancer NOS
EUCTR2006-006494-24-FRFédérationa Nationale des Centres de Lutte Contre le Cancer2,500
Active, not recruiting
Not Applicable
Study to evaluate the safety of two doses of Novartis Meningococcal Group B Vaccine when administered to healthy adults from 18 to 50 Years of age and to collect blood donations to develop vaccines against Neisseria Meningitidis
EUCTR2014-002972-95-PLovartis Pharma Services AG